Další formáty:
BibTeX
LaTeX
RIS
@article{1623023, author = {Hajek, Roman and Delforge, Michel and Raab, Marc S. and Schoen, Paul and DeCosta, Lucy and Spicka, Ivan and Radocha, Jakub and Pour, Luděk and GonzalezandMcQuire, Sebastian and Bouwmeester, Walter}, article_location = {Hoboken}, article_number = {4}, doi = {http://dx.doi.org/10.1111/bjh.16105}, keywords = {algorithm; multiple myeloma; overall survival; relapsed; risk stratification}, language = {eng}, issn = {0007-1048}, journal = {British journal of haematology}, title = {Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma}, url = {http://dx.doi.org/10.1111/bjh.16105}, volume = {187}, year = {2019} }
TY - JOUR ID - 1623023 AU - Hajek, Roman - Delforge, Michel - Raab, Marc S. - Schoen, Paul - DeCosta, Lucy - Spicka, Ivan - Radocha, Jakub - Pour, Luděk - Gonzalez-McQuire, Sebastian - Bouwmeester, Walter PY - 2019 TI - Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma JF - British journal of haematology VL - 187 IS - 4 SP - 447-458 EP - 447-458 PB - Wiley-Blackwell SN - 00071048 KW - algorithm KW - multiple myeloma KW - overall survival KW - relapsed KW - risk stratification UR - http://dx.doi.org/10.1111/bjh.16105 L2 - http://dx.doi.org/10.1111/bjh.16105 N2 - Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease-related factors change between diagnosis and the initiation of second-line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K-adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)-4 (highest risk) were 61 center dot 6, 29 center dot 6, 14 center dot 2 and 5 center dot 9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations. ER -
HAJEK, Roman, Michel DELFORGE, Marc S. RAAB, Paul SCHOEN, Lucy DECOSTA, Ivan SPICKA, Jakub RADOCHA, Luděk POUR, Sebastian GONZALEZ-MCQUIRE a Walter BOUWMEESTER. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. \textit{British journal of haematology}. Hoboken: Wiley-Blackwell, 2019, roč.~187, č.~4, s.~447-458. ISSN~0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.16105.
|